<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-11759R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007419</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Diabetes and Endocrinology/Obesity</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject><subject>Nutrition/Obesity</subject></subj-group></article-categories><title-group><article-title>Calprotectin &#x02014; A Novel Marker of Obesity</article-title><alt-title alt-title-type="running-head">Calprotectin and Obesity</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mortensen</surname><given-names>Ole Hartvig</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Anders Rinnov</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Erikstrup</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Plomgaard</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Christian Philip</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Krogh-Madsen</surname><given-names>Rikke</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lindegaard</surname><given-names>Birgitte</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Petersen</surname><given-names>Anne Marie</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Taudorf</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Bente Klarlund</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><addr-line>The Centre of Inflammation and Metabolism, Department of Infectious Diseases and Copenhagen Muscle Research Centre, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Vella</surname><given-names>Adrian</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Mayo Clinic College of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>bkp@rh.dk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: OHM ARN CPF BKP. Performed the experiments: OHM ARN CE PP CPF RKM BL AMP ST. Analyzed the data: OHM ARN BKP. Contributed reagents/materials/analysis tools: OHM CE PP CPF RKM BL AMP ST BKP. Wrote the paper: OHM ARN CE PP CPF RKM BL BKP.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2009</year></pub-date><volume>4</volume><issue>10</issue><elocation-id>e7419</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Mortensen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes.</p></sec><sec><title>Methodology/Principal Findings</title><p>Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p&#x0200a;&#x0003d;&#x0200a;0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p&#x0003c;0.0001), whereas it did not differ between obese and non-obese patients with T2D (p&#x0200a;&#x0003d;&#x0200a;0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-&#x003b1; or neutrophil number.</p></sec><sec><title>Conclusions/Significance</title><p>Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.</p></sec></abstract><counts><page-count count="4"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Recently, two novel inflammatory molecules belonging to the S100 protein family have been described, S100A8 (MRP8) and S100A9 (MRP14)<xref ref-type="bibr" rid="pone.0007419-Striz1">&#x0005b;1&#x0005d;</xref>. S100A8 and S100A9 form monovalent homodimers and a heterodimer, known as calprotectin, in a calcium-dependent manner. Both proteins are predominantly expressed in myeloid cells depending on the stage of cell differentiation and inflammatory status<xref ref-type="bibr" rid="pone.0007419-Striz1">&#x0005b;1&#x0005d;</xref>, however they have also been found to be expressed in skeletal muscle<xref ref-type="bibr" rid="pone.0007419-Rodriguez1">&#x0005b;2&#x0005d;</xref>. Studies on the regulation of S100A8 and S100A9 have shown that S100A9 seems to be ubiquitously expressed, while S100A8 can be induced by a variety of stimulants such as lipopolysaccharide, interferon-&#x003b3; and tumor necrosis factor-&#x003b1;<xref ref-type="bibr" rid="pone.0007419-Xu1">&#x0005b;3&#x0005d;</xref>. S100A8 and S100A9 take part in various processes of the innate immune response such as cell adhesion, chemotaxis, and antimicrobial activity<xref ref-type="bibr" rid="pone.0007419-Striz1">&#x0005b;1&#x0005d;</xref>. Phagocytes expressing S100A8 and S100A9 and elevated plasma calprotectin levels are found in a variety of chronic inflammatory conditions, including rheumatoid arthritis, allograft rejections, and inflammatory bowel and lung diseases<xref ref-type="bibr" rid="pone.0007419-Foell1">&#x0005b;4&#x0005d;</xref>. Calprotectin has also been found to be increased in plasma following exercise<xref ref-type="bibr" rid="pone.0007419-Mooren1">&#x0005b;5&#x0005d;</xref> and was recently shown to be released from skeletal muscle tissue <xref ref-type="bibr" rid="pone.0007419-Mortensen1">&#x0005b;6&#x0005d;</xref>.</p><p>We hypothesized that plasma calprotectin and skeletal muscle expression of S100A8 would be dysregulated in individuals with systemic inflammation. As low-grade systemic inflammation is a hallmark of both obesity and type 2 diabetes (T2D) we studied the levels of plasma calprotectin and S100A8 skeletal muscle mRNA levels using a cross-sectional case control design in which patients with T2D and healthy controls were closely matched, not only according to age and sex but also according to body mass index (BMI).</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Cohort study</title><sec id="s2a1"><title>Ethics Statement</title><p>The participants received oral and written information about the experimental procedures before giving their written informed consent. The study was approved by the Ethical Committee of Copenhagen and Frederiksberg Communities, Denmark (KF 01-141/04), and performed according to the Declaration of Helsinki.</p></sec></sec><sec id="s2b"><title>Subjects</title><p>A cross-sectional design was employed. Participants (n&#x02009;&#x0200a;&#x0003d;&#x0200a;&#x02009;199) were divided into 4 groups according to BMI (above or below 30 kg/m2) and diagnosis of T2D. Subjects and protocol have previously been described<xref ref-type="bibr" rid="pone.0007419-Krabbe1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007419-Plomgaard1">&#x0005b;8&#x0005d;</xref>.</p></sec><sec id="s2c"><title>Protocol</title><p>Participants reported in the laboratory between 8 and 10 am after an overnight fast. They did not take any medication in the 24 h preceding the examination and those with T2D did not take oral antidiabetic medication for one week prior to examination day. A general health examination was performed; blood samples were drawn from an antecubital vein, a skeletal muscle biopsy was obtained, an oral glucose tolerance test (OGTT), a fitness test was performed, and subjects were scanned on a dual-energy X-ray absorptiometry whole body scanner as previously described<xref ref-type="bibr" rid="pone.0007419-Krabbe1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007419-Plomgaard1">&#x0005b;8&#x0005d;</xref>.</p></sec><sec id="s2d"><title>Blood analysis</title><p>Plasma calprotectin was measured using a commercial Enzyme Linked Immunosorbent Assay (ELISA) kit (Hycult biotechnology, Uden, NL). All measurements were performed in duplicate. Analysis of other plasma parameters has been previously described<xref ref-type="bibr" rid="pone.0007419-Krabbe1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007419-Plomgaard1">&#x0005b;8&#x0005d;</xref>.</p></sec><sec id="s2e"><title>Skeletal muscle tissue S100A8 mRNA</title><p>Skeletal muscle tissue biopsies were obtained from musculus quadriceps and RNA isolated as previously described<xref ref-type="bibr" rid="pone.0007419-Plomgaard1">&#x0005b;8&#x0005d;</xref>. Following cDNA synthesis (Applied Biosystems, Foster City, CA, USA), real-time PCR was performed on an ABI 7900 Sequence Detection System (Applied Biosystems) using pre-developed TaqMan assays (Applied Biosystems) for S100A8 (Hs00374263_m1) and the endogenous control, &#x003b2;-actin. The mRNA content of both targets and the endogenous control, &#x003b2;-actin, was calculated from the cycle threshold values using the standard curve method and relative expression of S100A8 determined after normalisation to &#x003b2;-actin.</p></sec><sec id="s2f"><title>Statistics</title><p>All analyses were performed with SAS 9.1.2 (SAS Institute, Cary, NC, USA. Plasma levels of triglycerides (TAG), glucose, insulin, HOMA2-IR, HbA1c, IL-6, TNF-&#x003b1;, c-reactive protein (CRP), plasma calprotectin, fitness (expressed as VO<sub>2max</sub> pr. kg fat free mass), and S100A8 mRNA levels were log10-transformed to approximate normal distribution. For these parameters results are presented as geometric means with 95&#x00025; confidence intervals (CIs). For all other parameters results are presented as means with CIs. Differences between glycaemia and obesity groups were tested in a two-way analysis of variance (ANOVA) (PROC GLM with the LSMEANS statement using Tukey HSD as post-hoc test). Univariate and multivariate regression analysis (PROC REG) was performed with plasma calprotectin as the dependent variable and parameters of obesity, inflammation, metabolism, and T2D as explanatory variables. Results are presented as regression coefficients with CIs. P&#x0003c;0.05 was considered significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Plasma calprotectin is increased in obese subjects</title><p>General characteristics of the study population are shown in <xref ref-type="table" rid="pone-0007419-t001">Table 1</xref>. For plasma calprotectin, an interaction was found between glycemia group and obesity in a two-way ANOVA (p&#x0200a;&#x0003d;&#x0200a;0.012). Post-hoc tests showed that plasma calprotectin was increased in obese relative to non-obese controls (p&#x0003c;0.0001), whereas plasma calprotectin did not differ between obese and non-obese patients with T2D (p&#x0200a;&#x0003d;&#x0200a;0.62) (<xref ref-type="fig" rid="pone-0007419-g001">Fig. 1A</xref>). The difference in plasma calprotectin between obese and non-obese controls persisted after adjusting for age and sex. Skeletal muscle S100A8 mRNA levels did not differ between groups (<xref ref-type="fig" rid="pone-0007419-g001">Fig. 1B</xref>).</p><fig id="pone-0007419-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007419.g001</object-id><label>Figure 1</label><caption><title>Plasma calprotectin and skeletal muscle mRNA levels in humans.</title><p>A) Plasma concentrations of calprotectin are shown for the following four groups: Normal glucose tolerance (NGT)/Non-obese (N&#x0200a;&#x0003d;&#x0200a;62), NGT/obese (N&#x0200a;&#x0003d;&#x0200a;41), type 2 diabetes (T2D)/non-obese (N&#x0200a;&#x0003d;&#x0200a;50), T2D/obese (N&#x0200a;&#x0003d;&#x0200a;46). Data are expressed as geometric means; error bars represent 95&#x00025; confidence intervals (CIs). B) Skeletal muscle S100A8 mRNA are shown for the following four groups: NGT/Non-obese (N&#x0200a;&#x0003d;&#x0200a;53), NGT/obese (N&#x0200a;&#x0003d;&#x0200a;37), T2D/non-obese (N&#x0200a;&#x0003d;&#x0200a;44), T2D/obese (N&#x0200a;&#x0003d;&#x0200a;31). Data are expressed as geometric means; error bars represent CIs. C) Log-transformed plasma concentrations of calprotectin, log(p-calprotectin), and BMI, with circles and crosses depicting NGT and T2D subjects, respectively. There was a significant correlation between log(p-calprotectin) and BMI (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.112, p&#x0003c;0.0001).</p></caption><graphic xlink:href="pone.0007419.g001"/></fig><table-wrap id="pone-0007419-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007419.t001</object-id><label>Table 1</label><caption><title>General characteristics of the study population and plasma calprotectin univariate and multivariate regression analysis.</title></caption><alternatives><graphic id="pone-0007419-t001-1" xlink:href="pone.0007419.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="9" align="left" rowspan="1">Subject characteristics</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="5" align="left" rowspan="1">Regression analyses</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Normal Glucose Tolerance</td><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Type 2 Diabetes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Univariate</td><td colspan="3" align="left" rowspan="1">Multivariate</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Non-obese</td><td colspan="2" align="left" rowspan="1">Obese</td><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Non-obese</td><td colspan="2" align="left" rowspan="1">Obese</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RC</td><td align="left" rowspan="1" colspan="1">p-value</td><td align="left" rowspan="1" colspan="1">RC</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">n (male/female)</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">(42/20)</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">(28/13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">(38/12)</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">(34/12)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">(53&#x02013;59)</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">(45&#x02013;52)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">(55&#x02013;61)</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">(55&#x02013;61)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">per unit</td><td align="left" rowspan="1" colspan="1">0.993</td><td align="left" rowspan="1" colspan="1">0.0019</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (&#x00025;)</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">(27&#x00025;)</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">(24&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">(22&#x00025;)</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">(20&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fitness (VO<sub>2</sub>/kg/FFM)</td><td align="left" rowspan="1" colspan="1">49.2</td><td align="left" rowspan="1" colspan="1">(45.8&#x02013;52.9)</td><td align="left" rowspan="1" colspan="1">39.7</td><td align="left" rowspan="1" colspan="1">(36.4&#x02013;43.2)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">39.1</td><td align="left" rowspan="1" colspan="1">(35.9&#x02013;42.7)</td><td align="left" rowspan="1" colspan="1">34.7</td><td align="left" rowspan="1" colspan="1">(31.7&#x02013;37.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">0.713</td><td align="left" rowspan="1" colspan="1">0.0888</td><td align="left" rowspan="1" colspan="1">0.585</td><td align="left" rowspan="1" colspan="1">(0.379&#x02013;0.903)</td><td align="left" rowspan="1" colspan="1">0.0159</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">(0.88&#x02013;0.94)</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">(0.97&#x02013;1.01)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">(0.94&#x02013;0.98)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">(0.98&#x02013;1.02)</td><td align="left" rowspan="1" colspan="1">&#x0002a;</td><td align="left" rowspan="1" colspan="1">#</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">4.279</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">25.7</td><td align="left" rowspan="1" colspan="1">(24.8&#x02013;26.6)</td><td align="left" rowspan="1" colspan="1">36.7</td><td align="left" rowspan="1" colspan="1">(35.6&#x02013;37.8)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">26.6</td><td align="left" rowspan="1" colspan="1">(25.6&#x02013;27.6)</td><td align="left" rowspan="1" colspan="1">35.5</td><td align="left" rowspan="1" colspan="1">(34.4&#x02013;36.5)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">3.983</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">3.184</td><td align="left" rowspan="1" colspan="1">(1.665&#x02013;6.087)</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">Total fat mass (kg)</td><td align="left" rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">(18.1&#x02013;22.9)</td><td align="left" rowspan="1" colspan="1">44.3</td><td align="left" rowspan="1" colspan="1">(41.4&#x02013;47.2)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">(20.8&#x02013;25.0)</td><td align="left" rowspan="1" colspan="1">37.5</td><td align="left" rowspan="1" colspan="1">(35.3&#x02013;39.7)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">per unit</td><td align="left" rowspan="1" colspan="1">1.008</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">1.007</td><td align="left" rowspan="1" colspan="1">(1.003&#x02013;1.011)</td><td align="left" rowspan="1" colspan="1">0.0018</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>metabolic regulation</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p-HDL (mM)</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">(1.5&#x02013;1.8)</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.4)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.4)</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">per unit</td><td align="left" rowspan="1" colspan="1">0.784</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">0.846</td><td align="left" rowspan="1" colspan="1">(0.740&#x02013;0.846)</td><td align="left" rowspan="1" colspan="1">0.0138</td></tr><tr><td align="left" rowspan="1" colspan="1">p-LDL (mM)</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">(3.4&#x02013;3.9)</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">(3.0&#x02013;3.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">(2.6&#x02013;3.2)</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">(2.7&#x02013;3.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">per unit</td><td align="left" rowspan="1" colspan="1">0.969</td><td align="left" rowspan="1" colspan="1">0.2062</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">p-TAG (mM)</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">(0.9&#x02013;1.2)</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.7)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">(1.3&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.269</td><td align="left" rowspan="1" colspan="1">0.0063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">p-Glucose (mM)</td><td align="left" rowspan="1" colspan="1">5.1</td><td align="left" rowspan="1" colspan="1">(5.0&#x02013;5.2)</td><td align="left" rowspan="1" colspan="1">5.2</td><td align="left" rowspan="1" colspan="1">(5.1&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9.1</td><td align="left" rowspan="1" colspan="1">(8.2&#x02013;10.1)</td><td align="left" rowspan="1" colspan="1">9.0</td><td align="left" rowspan="1" colspan="1">(8.0&#x02013;10.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.184</td><td align="left" rowspan="1" colspan="1">0.2514</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">p-Insulin (pM)</td><td align="left" rowspan="1" colspan="1">34.8</td><td align="left" rowspan="1" colspan="1">(29.8&#x02013;40.6)</td><td align="left" rowspan="1" colspan="1">68.6</td><td align="left" rowspan="1" colspan="1">(56.9&#x02013;82.6)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">52.6</td><td align="left" rowspan="1" colspan="1">(43.3&#x02013;64.0)</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">(82.5&#x02013;124.0)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.278</td><td align="left" rowspan="1" colspan="1">0.0011</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA2-IR</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">(0.56&#x02013;0.76)</td><td align="left" rowspan="1" colspan="1">1.28</td><td align="left" rowspan="1" colspan="1">(1.07&#x02013;1.54)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">1.22</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;1.50)</td><td align="left" rowspan="1" colspan="1">2.27</td><td align="left" rowspan="1" colspan="1">(1.83&#x02013;2.81)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.266</td><td align="left" rowspan="1" colspan="1">0.0009</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (&#x00025;)</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="left" rowspan="1" colspan="1">(5.4&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">(5.5&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">(6.9&#x02013;7.8)</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">(6.5&#x02013;7.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">per unit</td><td align="left" rowspan="1" colspan="1">1.028</td><td align="left" rowspan="1" colspan="1">0.1086</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ns</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Inflammation</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">p-CRP (mg/l)</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">(1.3&#x02013;1.9)</td><td align="left" rowspan="1" colspan="1">3.9</td><td align="left" rowspan="1" colspan="1">(3.1&#x02013;5.0)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">(1.8&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">(2.9&#x02013;4.8)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.445</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">1.419</td><td align="left" rowspan="1" colspan="1">(1.249&#x02013;1.612)</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">p-TNF&#x003b1; (ng/l)</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">(2.2&#x02013;2.4)</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">(2.4&#x02013;2.8)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">(2.4&#x02013;2.8)</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">(2.6&#x02013;3.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">##</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.720</td><td align="left" rowspan="1" colspan="1">0.0212</td><td align="left" rowspan="1" colspan="1">1.624</td><td align="left" rowspan="1" colspan="1">(1.015&#x02013;2.597)</td><td align="left" rowspan="1" colspan="1">0.0431</td></tr><tr><td align="left" rowspan="1" colspan="1">p-IL-6 (ng/l)</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">(0.78&#x02013;1.1)</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">(1.6&#x02013;2.7)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">(1.2&#x02013;1.8)</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">(1.5&#x02013;2.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">1.406</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">1.406</td><td align="left" rowspan="1" colspan="1">(1.223&#x02013;1.617)</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils (10<sup>9</sup>/l)</td><td align="left" rowspan="1" colspan="1">2.91</td><td align="left" rowspan="1" colspan="1">(2.65&#x02013;3.19)</td><td align="left" rowspan="1" colspan="1">3.54</td><td align="left" rowspan="1" colspan="1">(3.19&#x02013;3.94)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">3.76</td><td align="left" rowspan="1" colspan="1">(3.39&#x02013;4.16)</td><td align="left" rowspan="1" colspan="1">3.88</td><td align="left" rowspan="1" colspan="1">(3.52&#x02013;4.28)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">###</td><td align="left" rowspan="1" colspan="1">pf10inc</td><td align="left" rowspan="1" colspan="1">2.748</td><td align="left" rowspan="1" colspan="1">0.0001</td><td align="left" rowspan="1" colspan="1">2.702</td><td align="left" rowspan="1" colspan="1">(2.000&#x02013;3.649)</td><td align="left" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">p-Calprotectin (ng/ml)</td><td align="left" rowspan="1" colspan="1">58.7</td><td align="left" rowspan="1" colspan="1">(54.1&#x02013;63.7)</td><td align="left" rowspan="1" colspan="1">81.2</td><td align="left" rowspan="1" colspan="1">(73.1&#x02013;90.2)</td><td align="left" rowspan="1" colspan="1">&#x0002a;&#x0002a;&#x0002a;</td><td align="left" rowspan="1" colspan="1">68.0</td><td align="left" rowspan="1" colspan="1">(61.8&#x02013;74.8)</td><td align="left" rowspan="1" colspan="1">73.8</td><td align="left" rowspan="1" colspan="1">(66.7&#x02013;81.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>The study population was divided into 4 groups on the basis of obesity (above or below 30 kg/m<sup>2</sup>) and diagnosis of type 2 diabetes (T2D): Normal glucose tolerance (NGT)/Non-obese, NGT/Obese, T2D/Non-obese and T2D/Obese. Data are presented as numbers for categorical variables and as means or geometric means with 95&#x00025; confidence interval (CI) for continuous variables. #) Difference between glycemia group (NGT vs. T2D); #) p&#x0003c;0.05, ##) p&#x0003c;0.01, ###) p&#x0003c;0.001. &#x0002a;) Difference between obesity groups within each glycemia group. &#x0002a;) p&#x0003c;0.05, &#x0002a;&#x0002a;) p&#x0003c;0.01, &#x0002a;&#x0002a;&#x0002a;) p&#x0003c;0.001. For age, BMI, total fat mass, p-HDL, p-TAG, p-IL-6, and p-calprotectin, there was an interaction between glycemia group and obesity. Hence, analyses were stratified for glycemia group and only comparisons within glycemia groups are shown. As calprotectin levels were log-transformed to approximate a normal distribution, regression coefficients (RC) and 95&#x00025; CIs were back-transformed, hence estimating the factor change of calprotectin level attributable to a 1-unit change in the predictor (per unit) or to a per factor-of-10 increase (pf10inc). The multivariate analysis was adjusted for age, sex, current smoking and HOMA2-IR.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Plasma calprotectin is a marker of BMI</title><p>Univariate- and multivariate regression analyses with plasma calprotectin as the dependent variable are shown in <xref ref-type="table" rid="pone-0007419-t001">table 1</xref>. In univariate regression analysis, plasma calprotectin was positively associated with BMI (<xref ref-type="fig" rid="pone-0007419-g001">Fig. 1C</xref>), waist-hip-ratio (WHR), total fat mass, fasting insulin, HOMA2-IR, triglyceride, neutrophils and CRP, and negatively associated with HDL, LDL, IL-6, TNF&#x003b1;, and there was a trend for VO<sub>2max</sub>. In multiple regression analysis (adjusting for age, sex, current smoking and HOMA2-IR), plasma calprotectin was positively associated with BMI, total fat mass, neutrophils, CRP, TNF-&#x003b1;, IL-6, and negatively associated with HDL (<xref ref-type="table" rid="pone-0007419-t001">table 1</xref>). When we further adjusted for VO<sub>2max</sub>, plasma calprotectin was no longer associated with TNF-&#x003b1; (p&#x0200a;&#x0003d;&#x0200a;0.053). Plasma calprotectin was associated with BMI after adjustment for CRP (p&#x0200a;&#x0003d;&#x0200a;0.042), TNF-&#x003b1; (p&#x0200a;&#x0003d;&#x0200a;0.0007), and neutrophils (p&#x0200a;&#x0003d;&#x0200a;0.011), but just failed to reach significance after adjustment for IL-6 (p&#x0200a;&#x0003d;&#x0200a;0.051).</p></sec></sec><sec id="s4"><title>Discussion</title><p>In the present study we demonstrated that obese subjects have elevated plasma calprotectin compared to non-obese healthy controls. In a multivariate regression analysis adjusted for age, sex, smoking and fasting insulin we found a strong positive correlation of plasma calprotectin with BMI, even when adjusting for CRP and neutrophil number. Even though calprotectin has been found to be expressed in and released from skeletal muscle <xref ref-type="bibr" rid="pone.0007419-Rodriguez1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007419-Mortensen1">&#x0005b;6&#x0005d;</xref>, we found no evidence of a dysregulation of one subunit of calprotectin, S100A8, in obese or type 2 diabetic subjects on the mRNA level, suggesting that the increased levels of calprotectin seen in obese subjects are derived from another source than skeletal muscle or that the level of S100A8 mRNA in skeletal muscle in humans has too much individual variation compared with plasma calprotectin. In support of this, we found no correlation between plasma calprotectin and S100A8 mRNA (data not shown). However, whether or not an increase in S100A8 mRNA is required for an increase in release of calprotectin from skeletal muscle is currently unknown. One may speculate that the increase in plasma IL-6 seen in healthy obese subjects compared to lean subjects may be the driving force behind the increase in plasma calprotectin in healthy obese subjects, as IL-6 is known to upregulate S100A8 and S100A9 mRNA in skeletal muscle <xref ref-type="bibr" rid="pone.0007419-Mortensen1">&#x0005b;6&#x0005d;</xref>, although an acute increase in systemic IL-6 levels did not increase plasma calprotectin <xref ref-type="bibr" rid="pone.0007419-Mortensen1">&#x0005b;6&#x0005d;</xref>.</p><p>Interestingly, serum calprotectin and expression in monocytes have been found to be increased in type 1 diabetes patients and have been suggested to be involved in the pathogenesis of type 1 diabetes<xref ref-type="bibr" rid="pone.0007419-Bouma1">&#x0005b;9&#x0005d;</xref>. However, in the current study, we found no correlation between plasma calprotectin and parameters of glucose homeostasis in the multivariate regression analysis, suggesting the role of calprotectin in glucose homeostasis regulation is minimal.</p><p>Heterodimeric S100A8/S100A9, the form measued in this study, but not the monomeric forms, has been shown to increase detrimental effects caused by advanced end glycation products (AGEs) and may therefore play a role in triggering atherosclerosis in subjects associated with high levels of AGEs<xref ref-type="bibr" rid="pone.0007419-Ehlermann1">&#x0005b;10&#x0005d;</xref>. The negative correlation between HDL cholesterol and plasma calprotectin may thus indicate a role for calprotectin in the pathogenesis of atherosclerosis. However, whether or not calprotectin directly contributes to any pathological mechanisms in obese subjects is presently unknown but warrants further investigation.</p><p>In conclusion, we found that high plasma calprotectin levels were a marker of obesity independently of classical inflammation markers such as CRP, TNF-&#x003b1; and circulating neutrophil number.</p></sec></body><back><ack><p>The authors are grateful for the excellent technical assistance of Hanne Villumsen, Ruth Rousing and Bettina Mentz.</p></ack><ref-list><title>References</title><ref id="pone.0007419-Striz1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Striz</surname><given-names>I</given-names></name><name><surname>Trebichavsky</surname><given-names>I</given-names></name></person-group><year>2004</year><article-title>Calprotectin - a pleiotropic molecule in acute and chronic inflammation.</article-title><source>Physiol Res</source><volume>53</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">15209531</pub-id></mixed-citation></ref><ref id="pone.0007419-Rodriguez1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Hilvo</surname><given-names>M</given-names></name><name><surname>Kytomaki</surname><given-names>L</given-names></name><name><surname>Fleming</surname><given-names>RE</given-names></name><name><surname>Britton</surname><given-names>RS</given-names></name><etal/></person-group><year>2007</year><article-title>Effects of iron loading on muscle: genome-wide mRNA expression profiling in the mouse.</article-title><source>BMC Genomics</source><volume>8</volume><fpage>379</fpage><pub-id pub-id-type="pmid">17949489</pub-id></mixed-citation></ref><ref id="pone.0007419-Xu1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Geczy</surname><given-names>CL</given-names></name></person-group><year>2000</year><article-title>IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8.</article-title><source>J Immunol</source><volume>164</volume><fpage>4916</fpage><lpage>4923</lpage><pub-id pub-id-type="pmid">10779802</pub-id></mixed-citation></ref><ref id="pone.0007419-Foell1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name></person-group><year>2004</year><article-title>Proinflammatory S100 proteins in arthritis and autoimmune disease.</article-title><source>Arthritis Rheum</source><volume>50</volume><fpage>3762</fpage><lpage>3771</lpage><pub-id pub-id-type="pmid">15593206</pub-id></mixed-citation></ref><ref id="pone.0007419-Mooren1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mooren</surname><given-names>FC</given-names></name><name><surname>Lechtermann</surname><given-names>A</given-names></name><name><surname>Fobker</surname><given-names>M</given-names></name><name><surname>Brandt</surname><given-names>B</given-names></name><name><surname>Sorg</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>The response of the novel pro-inflammatory molecules S100A8/A9 to exercise.</article-title><source>Int J Sports Med</source><volume>27</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">16944403</pub-id></mixed-citation></ref><ref id="pone.0007419-Mortensen1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>OH</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>C</given-names></name><name><surname>Nielsen</surname><given-names>AR</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><etal/></person-group><year>2008</year><article-title>Calprotectin is released from human skeletal muscle tissue during exercise.</article-title><source>J Physiol</source><volume>586</volume><fpage>3551</fpage><lpage>3562</lpage><pub-id pub-id-type="pmid">18511485</pub-id></mixed-citation></ref><ref id="pone.0007419-Krabbe1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krabbe</surname><given-names>KS</given-names></name><name><surname>Nielsen</surname><given-names>AR</given-names></name><name><surname>Krogh-Madsen</surname><given-names>R</given-names></name><name><surname>Plomgaard</surname><given-names>P</given-names></name><name><surname>Rasmussen</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Brain-derived neurotrophic factor (BDNF) and type 2 diabetes.</article-title><source>Diabetologia</source><volume>50</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">17151862</pub-id></mixed-citation></ref><ref id="pone.0007419-Plomgaard1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plomgaard</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>AR</given-names></name><name><surname>Fischer</surname><given-names>CP</given-names></name><name><surname>Mortensen</surname><given-names>OH</given-names></name><name><surname>Broholm</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes.</article-title><source>Diabetologia</source><volume>50</volume><fpage>2562</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">17928988</pub-id></mixed-citation></ref><ref id="pone.0007419-Bouma1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouma</surname><given-names>G</given-names></name><name><surname>Lam-Tse</surname><given-names>WK</given-names></name><name><surname>Wierenga-Wolf</surname><given-names>AF</given-names></name><name><surname>Drexhage</surname><given-names>HA</given-names></name><name><surname>Versnel</surname><given-names>MA</given-names></name></person-group><year>2004</year><article-title>Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin.</article-title><source>Diabetes</source><volume>53</volume><fpage>1979</fpage><lpage>1986</lpage><pub-id pub-id-type="pmid">15277376</pub-id></mixed-citation></ref><ref id="pone.0007419-Ehlermann1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehlermann</surname><given-names>P</given-names></name><name><surname>Eggers</surname><given-names>K</given-names></name><name><surname>Bierhaus</surname><given-names>A</given-names></name><name><surname>Most</surname><given-names>P</given-names></name><name><surname>Weichenhan</surname><given-names>D</given-names></name><etal/></person-group><year>2006</year><article-title>Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products.</article-title><source>Cardiovasc Diabetol</source><volume>5</volume><fpage>6</fpage><pub-id pub-id-type="pmid">16573830</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The Centre of Inflammation and Metabolism is supported by a grant from the Danish National Research Foundation (# 02-512-55). This study was further supported by the Danish Medical Research Council, the Commission of the European Communities (contract no. LSHM-CT-2004-005272 EXGENESIS), and by grants from Gangstedfonden and Direkt&#x000f8;r Emil Hertz og Hustru Inger Hertz Fond. The Copenhagen Muscle Research Centre is supported by grants from the Capital Region of Denmark and the University of Copenhagen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>